ARA-290, also known as cibinetide, is a synthetic peptide composed of 11 amino-acid residues. It was designed from a structural region of erythropoietin, or EPO, to investigate tissue-protective signaling separately from EPO’s role in stimulating red blood cell production. The FDA’s cibinetide substance record lists ARA-290 and ARA 290 among its alternative names. PubMed Central (PMC)

Published research includes laboratory experiments, animal models, and small human studies involving sarcoidosis-associated small fiber neuropathy and diabetes-related neuropathic symptoms. Those studies provide a scientific basis for further investigation, but their findings should not be treated as proof of broad clinical benefits. pubmed.ncbi.nlm.nih.gov

For background on how these compounds are studied, see our guide to What Are Research Peptides?.

How Is ARA-290 Related to Erythropoietin?

Erythropoietin is a protein involved in regulating red blood cell production. Researchers have also investigated its involvement in cellular responses to injury. ARA-290 emerged from efforts to separate these activities: scientists modeled a short peptide on the outward-facing surface of EPO’s helix B region rather than reproducing the entire protein. PubMed Central (PMC)

The foundational peptide-design study reported tissue-protective activity in experimental models without the red-blood-cell-stimulating activity associated with EPO. This is the basis for describing ARA-290 as nonerythropoietic. That term describes a biological distinction; it does not establish that the compound is free of risks. PubMed Central (PMC)

How Does ARA-290 Work in Research Models?

ARA-290 research frequently focuses on the innate repair receptor, abbreviated IRR. The proposed receptor complex includes the erythropoietin receptor, or EPOR, and the beta-common receptor subunit, also called CD131. Investigators study whether signaling involving this complex affects inflammation, cell survival, and responses to tissue injury. PubMed Central (PMC)

Mechanistic experiments help test that explanation. In a mouse study of cerebral ischemia, researchers examined ARA-290 alongside suppression of the beta-common receptor. Suppressing that receptor reduced several measured effects, supporting its involvement in that particular model. PubMed Central (PMC)

These findings help explain the scientific interest in ARA-290, but a mechanism observed in an experimental model does not establish the same response in every tissue, disease, or person.

For another peptide-research overview, see What Is KPV?. Each compound’s mechanism and evidence need to be evaluated separately.

What Has ARA-290 Been Studied For?

Small Fiber Neuropathy Associated With Sarcoidosis

Small nerve fibers contribute to pain and temperature sensation and to autonomic functions. Several ARA-290 studies have examined people with sarcoidosis who also had symptoms or evidence of small fiber involvement. Researchers have measured both patient-reported symptoms and structural features of small nerves. Europe PMC

A randomized, double-blind pilot trial involving 22 participants found a greater improvement in a small fiber neuropathy symptom questionnaire with ARA-290 than with placebo over four weeks. However, other measures—including the Brief Pain Inventory and fatigue scores—improved similarly in both groups. The results therefore differed depending on the outcome being assessed. PubMed

A separate placebo-controlled study reported changes in neuropathic symptoms, corneal nerve fiber density, and selected sensory and functional measurements. These findings supported further investigation of whether changes in nerve structure might accompany changes in symptoms. Europe PMC

A subsequent phase 2b trial involving 64 participants evaluated corneal nerve fiber area over 28 days. One treatment group showed a statistically significant improvement in that primary measurement compared with placebo. However, the highlighted placebo-adjusted pain comparison in participants with moderate-to-severe pain did not reach statistical significance. IOVS

A change in a nerve-fiber measurement is not automatically the same as a demonstrated improvement in pain or everyday function. That distinction is essential when interpreting this research.

Diabetes-Related Neuropathic Symptoms

A phase 2 study in participants with type 2 diabetes and painful neuropathy investigated ARA-290 over a 28-day treatment period, followed by an additional month of observation. Researchers reported changes in neuropathic symptom scores, HbA1c, and lipid measurements. PubMed

Corneal nerve findings also depended on the participants’ starting measurements: an increase in nerve fiber density was reported in a subgroup with reduced baseline density. This is more specific than claiming that every participant experienced nerve regeneration. The findings supported further evaluation, not a conclusion that ARA-290 is an established diabetes treatment. PubMed

Cellular Stress and Experimental Tissue Injury

ARA-290 has also been investigated outside neuropathy studies.

In a kidney ischemia-reperfusion study in pigs, researchers examined kidney function and structural injury after blood supply was interrupted and restored. The study reported differences in kidney function and fibrosis-related findings, providing a rationale for additional research rather than evidence of a proven human kidney treatment. PubMed Central (PMC)

Another study of isolated human pancreatic islets investigated cellular responses to inflammatory conditions and transplantation into mice. Researchers examined measures including cellular energy, cell-death signaling, insulin secretion, and engraftment. Although the experiments used human cells, the transplantation portion was an animal experiment—not a clinical trial in human transplant recipients. NCBI

These examples illustrate why the research setting matters. A cell-culture result, an animal experiment, and a controlled human trial answer different questions.

What Are the Main Limitations of the Evidence?

The human studies discussed above were relatively small and generally used short treatment periods. Such designs can identify signals worth investigating, but they cannot establish long-term safety, reliably detect uncommon adverse effects, or demonstrate that findings apply to a much broader population. pubmed.ncbi.nlm.nih.gov

Another limitation is the difference between surrogate measurements and outcomes that people directly experience. Corneal nerve measurements can help researchers investigate biological changes, but they should be considered alongside symptoms and function—not treated as interchangeable with them. IOVS

Research sponsorship also deserves attention. Several publications include authors affiliated with the compound’s developer. That does not invalidate the findings, but it reinforces the value of examining disclosures, study design, and independent replication rather than relying only on an abstract’s conclusion. PubMed

A useful way to read any ARA-290 paper is to ask: What was measured, what was the comparison, and which conclusions does that specific experiment actually support?

Does a Regulatory Database Listing Mean ARA-290 Is Approved?

No. A substance identifier and a drug approval serve different purposes.

The FDA’s cibinetide identity record provides names and identifying information for the substance. The FDA explicitly explains that the availability of a Unique Ingredient Identifier, or UNII, does not imply regulatory review or approval. precisionFDA

The European Medicines Agency’s cibinetide orphan-designation record likewise distinguishes orphan designation from marketing authorization. An orphan designation supports the development of a potential medicine for a rare condition; it is not confirmation that the product has demonstrated the quality, safety, and efficacy required for marketing authorization. European Medicines Agency (EMA)

Database entries and development designations therefore should not be presented as proof of an approved treatment.

How Should ARA-290 Be Compared With Other Research Peptides?

A meaningful comparison starts with the research question—not the fact that two compounds are both called peptides.

Consider whether the studies used comparable models, measured comparable outcomes, and included appropriate controls. A favorable finding for one compound cannot establish the same finding for another, and separate studies do not automatically provide a valid head-to-head comparison.

Our articles on What Is GHK-Cu? and What Is SS-31? provide additional research overviews to read with those distinctions in mind.

Frequently Asked Questions

Is ARA-290 the Same as Cibinetide?

Yes. The FDA’s substance identity record lists cibinetide as the preferred substance name and includes ARA-290, ARA 290, and ARA290 among its synonyms. precisionFDA

Has ARA-290 Been Studied in Humans?

Yes. Published studies include small controlled trials involving sarcoidosis-associated small fiber neuropathy and type 2 diabetes with neuropathic symptoms. The existence of human research does not, by itself, establish broad effectiveness or long-term safety. pubmed.ncbi.nlm.nih.gov

Do Published Studies Verify a Supplier’s Research Material?

No. A paper describes the material and experimental conditions used in that study. It does not, by itself, establish the identity, composition, or quality of a different supplier’s batch. Scientific literature and batch-specific analytical documentation answer different questions.

The Bottom Line

ARA-290 is a synthetic peptide designed to investigate EPO-related tissue-protective signaling separately from red blood cell stimulation. Its research includes small human trials and a range of experimental models. The important distinction is between an interesting biological finding and an established clinical benefit. PubMed Central (PMC)

For more educational articles, explore the Peptides Exchange Research Library.

Research Use Only

This article summarizes published research for educational purposes and does not provide medical advice or instructions for administration. Peptides Exchange products are intended strictly for in-vitro laboratory research by qualified professionals and are not for human or animal use or consumption. Peptides Exchange

Sources and Further Reading

1. Brines and colleagues — peptide design: Foundational research on nonerythropoietic peptides modeled on erythropoietin. Proceedings of the National Academy of Sciences.
2. Wang and colleagues — receptor mechanism: ARA290 and beta-common receptor involvement in a mouse cerebral ischemia model. CNS Neuroscience & Therapeutics.
3. Heij and colleagues — human pilot trial: Randomized, double-blind study in sarcoidosis-associated small fiber neuropathy. Molecular Medicine.
4. Dahan and colleagues — symptoms and nerve measurements: Sarcoidosis study examining neuropathic symptoms and corneal nerve fiber density. Molecular Medicine.
5. Culver and colleagues — phase 2b trial: Cibinetide study assessing corneal nerve fiber abundance and neuropathic pain. Investigative Ophthalmology & Visual Science.
6. Brines and colleagues — diabetes-related research: Phase 2 study examining metabolic measurements and neuropathic symptoms. Molecular Medicine.
7. Van Rijt and colleagues — animal kidney research: ARA290 in a porcine renal ischemia-reperfusion model. Journal of Translational Medicine.
8. Yao and colleagues — cell and transplantation research: Cibinetide experiments involving isolated human islets and transplantation into mice. Cell Transplantation.
9. U.S. Food and Drug Administration: Cibinetide substance identity record and explanation of UNII limitations.
10. European Medicines Agency: Cibinetide orphan designation and the distinction from marketing authorization.